



# IS YOUR NEW RAPID TEST BEING DENIED ENTRY TO GLOBAL MARKETS?



**You have a great idea for a rapid test that has global market potential. Unfortunately, your marketing rights may be anything *but* global.**

While designing and manufacturing lateral flow rapid tests is relatively straightforward, marketing and selling these tests in the global marketplace is complicated by the numerous patents that govern the lateral flow platform, particularly in the most lucrative markets of North America and Europe. As you chart your course to the market, you should consider how severely these intellectual property roadblocks could limit your opportunities or worse yet, lead you down a path to litigation. MedMira can help.

Since 1994, MedMira has continually refined and advanced its Rapid Flow-Through (RFT) test platform, the basis for our own line of single and multiple rapid tests. MedMira's RFT platform is not only exceptionally rapid, robust, and accurate, it is also uniquely capable of generating **multiple test results on a single device**.

Now accessible to researchers and *in vitro* diagnostics manufacturers through affordable, world-wide licensing agreements, MedMira's patented RFT platform can help you take your rapid test to a market that is truly global.

## MedMira's RFT Platform

MedMira's market-ready RFT platform replaces the inherent complexity and limitations of earlier generations of flow-through platforms with simplicity, stability, and speed. Key features and benefits of our RFT include:

Time to Result:	3 minutes or less
Stability at 2 – 30C:	Up to 24 months
Maximum Volume of Sample and Buffer:	1 mL
Sample Types:	Whole blood, serum, plasma; other types of specimens including urine, oral fluid, fecal suspensions worked up upon request
Maximum Number of Analytes:	3 analyte reaction zones plus a control zone
Semi-quantitation:	3 reaction zones of different titres plus a control zone
Analyte Types:	Antigens, IgG, IgM, Protein A; other antibodies, small molecules worked up upon request
Conjugate Types:	Colloidal gold antibodies, antigens
Cassette Specifications:	Customizable size, shape, colors, graphics





## From the Lab to the Loading Dock

The swiftest route to the global market is to let MedMira's expert staff convert your existing test to MedMira's RFT platform. Platform conversions to RFT, including proof-of-concept and prototype device, can typically be made using reagents from existing lateral flow, latex, ELISA, IFA, or chemiluminescence tests within three to six months.



## Proven Quality Standards

MedMira operates an FDA-inspected facility and is fully compliant with GMP and ISO 13485 standards. Under the principles of Design Control, MedMira's development team can convert your test to the RFT platform and perform stability analyses. In addition, MedMira can manufacture your product under our proven quality systems, and customize your product's design and packaging to meet your sales and marketing requirements.



## Do-it-Yourself Tools

If you prefer to do your own conversion, or are just beginning the design phase, MedMira offers a Do-it-Yourself RFT Kit as an off-the-shelf package of RFT devices, conjugates, and assay development guidelines. If you need advice along the way, our team can help with that too. When you are ready for production, you can tap into MedMira's manufacturing expertise, or simply source your bulk components from MedMira.



## Go Global with MedMira

The global market is easily accessible with MedMira's Rapid Flow-Through Platform.

To learn more about MedMira's RFT Platform contact us today.

MedMira Inc.  
155 Chain Lake Drive, Suite 1  
Halifax, NS B3Z 1L3 Canada  
Tel.: +1 902 450-1588  
Fax: +1 902- 450 1580  
Email: [info@medmira.com](mailto:info@medmira.com)



Manufactured in Canada

All tests manufactured in Canada to ISO 13485:2003 standards in a GMP approved facility.  
Copyright 2008 MedMira Laboratories Inc.

[www.medmira.com](http://www.medmira.com)

**medmira**  
helping people know...®